FeedbackConsolidated Guidelines
References
- Global tuberculosis report. Ginebra: Organización Mundial de la Salud; 2020 (https://apps.who.int/iris/rest/bitstreams/1312164/retrieve, consultado el 3 de marzo del 2022).
- The end TB strategy. Ginebra: Organización Mundial de la Salud; 2015 (https://apps.who.int/iris/handle/10665/331326, consultado el 3 de marzo del 2022).
- Guidelines for treatment of drug-susceptible tuberculosis and patient care.
Research priorities
The GDGs discussed future research and highlighted a number of priorities.
1. The effectiveness of fixed-dose combination TB treatment when compared to separate drug formulations in patients with DS-TB disease
Web Annexes
Web Annex 1. Expert panels
Web Annex 2. Declarations of interest
Web Annex 3. PICO questions
Web Annex 4. GRADE evidence profiles and evidence-to-decision tables
Web Annex 5. 2010 and 2017 DS-TB Guidelines
https://apps.who.int/iris/bitstream/handle/10665/353398/9789240048140-eng.pdf
The use of adjuvant steroids in the treatment of TB meningitis and pericarditis
Recommendation 10.
In patients with tuberculous meningitis, an initial adjuvant corticosteroid therapy with dexamethasone or prednisolone tapered over 6-8 weeks should be used (strong recommendation, moderate certainty of evidence).
Recommendation 11.
In patients with tuberculous pericarditis, an initial adjuvant corticosteroid therapy may be used (conditional recommendation, very low certainty of evidence).
Source of recommendation
Drug-susceptible TB treatment and ART in people living with HIV
Recommendation 8.
It is recommended that TB patients who are living with HIV should receive at least the same duration of daily TB treatment as HIV-negative TB patients (strong recommendation, high certainty of evidence)
Source of recommendation
Treatment of drug-susceptible TB using 4-month regimens
Recommendation 6.
People aged 12 years or older with drug-susceptible pulmonary TB, may receive a 4-month regimen of isoniazid, rifapentine, moxifloxacin and pyrazinamide⁸ (conditional recommendation, moderate certainty of evidence) - new recommendation.
Source of recommendation
Treatment of drug-susceptible TB using 6-month regimen
Recommendation 1.
New patients with pulmonary TB should receive a regimen containing 6 months of rifampicin: 2HRZE/4HR (strong recommendation, high certainty of evidence)
Remarks
A: The recommendation also applies to extrapulmonary TB - except TB of the central nervous system, bone or joint for which some expert groups suggest longer therapy.
Publication, dissemination, implementation, evaluation and expiry
These guidelines are published on the website of WHO's Global TB Programme (WHO/GTB)⁶ and can be freely downloaded (in pdf and other electronic formats). It is also expected that the evidence reviews and recommendations will be published in peer-reviewed journals to improve dissemination of the main messages. The updates to policy guidance are also reflected in the implementation guidance on TB management and the revision of the WHO operational handbook on tuberculosis -Module 4: Treatment.